echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The exclusive varieties are missing!

    The exclusive varieties are missing!

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guangdong's 11-province alliance took the lead in opening the centralized collection of biological drugs, which involved 4 blood products.
    In addition, basic infusion also appeared in the collection for the first time
    .
    From the renewal of the bid of cephalexin in Guangdong, the collection of 45 varieties in 11 provinces, the collection of proprietary Chinese medicines, and the collection of 153 varieties this time, it can be seen that the coverage of local collections in the future is expanding.
    The “should use everything” and “do it in batches” are also gradually advancing
    .
    However, there are omissions in these 153 drug catalogs, and the Guangdong platform has issued a supplementary notice!
     
    On October 11, the Guangdong Provincial Drug Trading Center issued a supplementary notice on the "Guangdong Union Diclofenac and other 153 drug groups with volume procurement documents (draft for comments)"
    .
     
    After verification, the product serial number "128" of "Part III Other Drugs (Exclusive Drugs)" in the "Guangdong Union Diclofenac and Other 153 Drug Group Purchase Orders with Quantity" is omitted, and the following is added:
     
    The product name is "Ilaprazole", the medical insurance dosage form is "Oral regular-release dosage form", the product name is "Ilaprazole enteric-coated tablets", and the specific dosage form is "Enteric-coated tablets"
    .
     
    Prior to this (September 30), the Guangdong Provincial Pharmaceutical Exchange Center issued the "Guangdong Union Diclofenac and other 153 drug groups with volume procurement documents (draft for comments)", involving 153 varieties, including 3 blood products, 4 basic infusions and There are 146 other drugs, of which 50 are exclusive varieties (after grouping, now 51), see the attached table at the end of the article
    .
     
      The range of varieties purchased this time are all products with a large amount and a high purchase amount in the National Medical Insurance Catalog
    .
    Dosage forms or specifications of drugs that are not covered by the medical insurance catalog, nationally adopted drugs that have not expired, nationally negotiated drugs, drugs subject to special national management, and generic drugs that have passed (including deemed approved, the same below) consistency evaluation (as of August 12, 2021 Japan) corresponding formulations are not included in the scope of this collection
    .
     
      The alliance members participating in the reporting include 11 provinces (regions) in Guangdong, Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang, and Xinjiang Production and Construction Corps
    .
     
      Guangdong's 11-province alliance took the lead in opening the centralized collection of biological drugs, which involved 4 blood products.
    In addition, basic infusion also appeared in the collection for the first time
    .
    From the renewal of the bid of cephalexin in Guangdong, the collection of 45 varieties in 11 provinces, the collection of proprietary Chinese medicines, and the collection of 153 varieties this time, it can be seen that the coverage of local collections in the future is expanding.
    The “should use everything” and “do it in batches” are also gradually advancing
    .
    However, there are omissions in these 153 drug catalogs, and the Guangdong platform has issued a supplementary notice!
     
      On October 11, the Guangdong Provincial Drug Trading Center issued a supplementary notice on the "Guangdong Union Diclofenac and other 153 drug groups with volume procurement documents (draft for comments)"
    .
     
      After verification, the product serial number "128" of "Part III Other Drugs (Exclusive Drugs)" in the "Guangdong Union Diclofenac and Other 153 Drug Group Purchase Orders with Quantity" is omitted, and the following is added:
     
      The product name is "Ilaprazole", the medical insurance dosage form is "Oral regular-release dosage form", the product name is "Ilaprazole enteric-coated tablets", and the specific dosage form is "Enteric-coated tablets"
    .
     
      Prior to this (September 30), the Guangdong Provincial Pharmaceutical Exchange Center issued the "Guangdong Union Diclofenac and other 153 drug groups with volume procurement documents (draft for comments)", involving 153 varieties, including 3 blood products, 4 basic infusions and There are 146 other drugs, of which 50 are exclusive varieties (after grouping, now 51), see the attached table at the end of the article
    .
     
      The range of varieties purchased this time are all products with a large amount and a high purchase amount in the National Medical Insurance Catalog
    .
    Dosage forms or specifications of drugs that are not covered by the medical insurance catalog, nationally adopted drugs that have not expired, nationally negotiated drugs, drugs subject to special national management, and generic drugs that have passed (including deemed approved, the same below) consistency evaluation (as of August 12, 2021 Japan) corresponding formulations are not included in the scope of this collection
    .
     
      The alliance members participating in the reporting include 11 provinces (regions) in Guangdong, Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang, and Xinjiang Production and Construction Corps
    .
     
      Guangdong's 11-province alliance took the lead in opening the centralized collection of biological drugs, which involved 4 blood products.
    In addition, basic infusion also appeared in the collection for the first time
    .
    From the renewal of the bid of cephalexin in Guangdong, the collection of 45 varieties in 11 provinces, the collection of proprietary Chinese medicines, and the collection of 153 varieties this time, it can be seen that the coverage of local collections in the future is expanding.
    The “should use everything” and “do it in batches” are also gradually advancing
    .
    However, there are omissions in these 153 drug catalogs, and the Guangdong platform has issued a supplementary notice!
     
      On October 11, the Guangdong Provincial Drug Trading Center issued a supplementary notice on the "Guangdong Union Diclofenac and other 153 drug groups with volume procurement documents (draft for comments)"
    .
     
      After verification, the product serial number "128" of "Part III Other Drugs (Exclusive Drugs)" in the "Guangdong Union Diclofenac and Other 153 Drug Group Purchase Orders with Quantity" is omitted, and the following is added:
     
      The product name is "Ilaprazole", the medical insurance dosage form is "Oral regular-release dosage form", the product name is "Ilaprazole enteric-coated tablets", and the specific dosage form is "Enteric-coated tablets"
    .
     
      Prior to this (September 30), the Guangdong Provincial Pharmaceutical Exchange Center issued the "Guangdong Union Diclofenac and other 153 drug groups with volume procurement documents (draft for comments)", involving 153 varieties, including 3 blood products, 4 basic infusions and There are 146 other drugs, of which 50 are exclusive varieties (after grouping, now 51), see the attached table at the end of the article
    .
    Drug Drug Purchasing Procurement
     
      The range of varieties purchased this time are all products with a large amount and a high purchase amount in the National Medical Insurance Catalog
    .
    Dosage forms or specifications of drugs that are not covered by the medical insurance catalog, nationally adopted drugs that have not expired, nationally negotiated drugs, drugs subject to special national management, and generic drugs that have passed (including deemed approved, the same below) consistency evaluation (as of August 12, 2021 Japan) corresponding formulations are not included in the scope of this collection
    .
     
      The alliance members participating in the reporting include 11 provinces (regions) in Guangdong, Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang, and Xinjiang Production and Construction Corps
    .
     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.